POIS-Treatment: Dry Ejaculation as a Radical Therapy Option?
Hope or extreme exception? – A case report on the treatment of Postorgasmic-Illness-Syndrome
A recently published case report describes the dramatic journey of a POIS patient whose years of suffering ended with a radical surgical procedure. The outcome not only offers a potential clue to the underlying mechanisms of the condition, but also raises important questions about ethics and the wider applicability of such treatments.
POIS (Postorgasmic-Illness-Syndrome) is a rare but highly debilitating condition. Within minutes after orgasm, those affected experience flu-like symptoms such as severe fatigue, muscle pain, and concentration problems that can last up to a week. Since there are no standardized treatments, patients are often left to navigate their symptoms alone.
The new report focuses on a 33-year-old man whose POIS symptoms began after taking a dietary supplement designed to increase semen volume. Even after discontinuing the supplement, the symptoms persisted and led to a long series of interventions—including testicular removal and testosterone replacement therapy—which provided only temporary or insufficient relief.
The turning point came when the patient underwent surgery in India in which both seminal vesicles were removed. This resulted in a complete “dry ejaculation”—an orgasm without the release of seminal fluid. Remarkably, since the procedure, the man has been entirely symptom-free.
What does this mean for POIS research?
This case supports the hypothesis that an allergic reaction to the seminal fluid itself may trigger POIS. By surgically eliminating seminal fluid, the immune response was halted, leading to full recovery.
However, it is crucial to highlight the limitations of this report. The described treatment is extremely invasive and cannot be considered a general therapeutic recommendation. It represents an individual case that is not transferable to other POIS patients.
Conclusion
This case provides a fascinating, albeit radical, stimulus for further research. It underscores the urgent need to develop safer and standardized treatments that build on emerging insights into the underlying triggers of the condition.
The study was published in the April 2025 issue of the International Journal of Impotence Research.